Sign In
Buy KROS
$10.50
-0.0500 (-0.474%)
At Close: Jun 03, 2026
Keros Therapeutics, Inc. (KROS) Shareholders May Have Been Affected by Fraud - Levi & Korsinsky Investigates
10:30am, Wednesday, 22'nd Jan 2025
NEW YORK, NY / ACCESS Newswire / January 22, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Keros Therapeutics, Inc. ("Keros Therapeutics, Inc.") (NASDAQ:KROS) co
NEW YORK, NY / ACCESS Newswire / January 22, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Keros Therapeutics, Inc. ("Keros" or "the Company")
Keros Therapeutics (KROS) Soars 5.1%: Is Further Upside Left in the Stock?
09:55am, Wednesday, 22'nd Jan 2025
Keros Therapeutics (KROS) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions could translate into further price inc
NEW YORK, NY / ACCESS Newswire / January 21, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Keros Therapeutics, Inc. ("Keros Therapeutics, Inc.") (NASDAQ:KROS) co
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Keros Therapeutics, Inc. - KROS
06:15pm, Tuesday, 21'st Jan 2025
NEW YORK , Jan. 21, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Keros Therapeutics, Inc. ("Keros" or the "Company") (NASDAQ: KROS). Such investors are advised
Lost Money on Keros Therapeutics, Inc.(KROS)? Contact Levi & Korsinsky Regarding an Ongoing Investigation
10:30am, Tuesday, 21'st Jan 2025
NEW YORK, NY / ACCESS Newswire / January 21, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Keros Therapeutics, Inc. ("Keros Therapeutics, Inc.") (NASDAQ:KROS) co
NEW YORK, NY / ACCESS Newswire / January 21, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Keros Therapeutics, Inc. ("Keros" or "the Company")
NEW YORK, NY / ACCESS Newswire / January 20, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Keros Therapeutics, Inc. ("Keros Therapeutics, Inc.") (NASDAQ:KROS) co
Down -36.23% in 4 Weeks, Here's Why Keros Therapeutics (KROS) Looks Ripe for a Turnaround
10:40am, Monday, 20'th Jan 2025
The heavy selling pressure might have exhausted for Keros Therapeutics (KROS) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street
NEW YORK, NY / ACCESS Newswire / January 20, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Keros Therapeutics, Inc. ("Keros" or "the Company")
NEW YORK, NY / ACCESSWIRE / January 19, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Keros Therapeutics, Inc. ("Keros Therapeutics, Inc.") (NASDAQ:KROS) concern
NEW YORK, NY / ACCESS Newswire / January 19, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Keros Therapeutics, Inc. ("Keros" or "the Company")
Did Keros Therapeutics, Inc. Mislead Investors? Shareholder Rights Advocates at Levi & Korsinsky Investigate- KROS
06:01pm, Saturday, 18'th Jan 2025
NEW YORK, NY / ACCESSWIRE / January 18, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Keros Therapeutics, Inc. ("Keros Therapeutics, Inc.") (NASDAQ:KROS) concern
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Keros Therapeutics, Inc. - KROS
12:00pm, Saturday, 18'th Jan 2025
NEW YORK CITY, NY / ACCESS Newswire / January 18, 2025 / Pomerantz LLP is investigating claims on behalf of investors of Keros Therapeutics, Inc. ("Keros" or the "Company")(NASDAQ:KROS). Such investor
Keros Therapeutics, Inc. (KROS) Shareholders May Have Been Affected by Fraud - Levi & Korsinsky Investigates
11:00am, Friday, 17'th Jan 2025
NEW YORK CITY, NY / ACCESS Newswire / January 17, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Keros Therapeutics, Inc. ("Keros Therapeutics, Inc.") (NASDAQ:KRO
